{"id":"docetaxel-or-albumin-paclitaxel","safety":{"commonSideEffects":[{"rate":"75-90","effect":"Neutropenia"},{"rate":"50-70","effect":"Anemia"},{"rate":"25-50","effect":"Thrombocytopenia"},{"rate":"50-60","effect":"Peripheral neuropathy"},{"rate":"75-80","effect":"Alopecia"},{"rate":"40-50","effect":"Nausea/vomiting"},{"rate":"30-40","effect":"Diarrhea"},{"rate":"20-30","effect":"Mucositis"},{"rate":"5-10","effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL1201451","moleculeType":"Protein"},"_fixedAt":"2026-03-30T16:04:26.152636","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Both drugs are microtubule-stabilizing agents that bind to β-tubulin and promote microtubule assembly while inhibiting disassembly. This disrupts the dynamic instability of microtubules required for cell division, leading to G2/M phase arrest and triggering apoptosis in rapidly dividing cancer cells. Albumin-bound paclitaxel (nab-paclitaxel) uses albumin nanoparticles for improved solubility and tumor penetration compared to conventional paclitaxel formulations.","oneSentence":"Docetaxel and albumin-bound paclitaxel are taxane chemotherapy agents that stabilize microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:35:22.727Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Non-small cell lung cancer"},{"name":"Ovarian cancer"},{"name":"Gastric cancer"},{"name":"Head and neck cancer"}]},"_fixedFields":["pubmed(22746)"],"trialDetails":[{"nctId":"NCT04310007","phase":"PHASE2","title":"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-13","conditions":"Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":117},{"nctId":"NCT04266249","phase":"PHASE2","title":"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-03-13","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8","enrollment":2175},{"nctId":"NCT05281471","phase":"PHASE3","title":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2022-08-31","conditions":"Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer","enrollment":186},{"nctId":"NCT05633667","phase":"PHASE2","title":"Study of Novel Treatment Combinations in Patients With Lung Cancer","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-03-16","conditions":"Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer","enrollment":270},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT05753306","phase":"PHASE2","title":"Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-04-20","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum","enrollment":40},{"nctId":"NCT07328854","phase":"PHASE3","title":"40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-11-20","conditions":"Nasopharyngeal Carcinoma","enrollment":346},{"nctId":"NCT06741644","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"CStone Pharmaceuticals","startDate":"2025-02-24","conditions":"Advanced Solid Tumors","enrollment":660},{"nctId":"NCT07239271","phase":"PHASE3","title":"A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation Model","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-11-16","conditions":"Patients With HER2-positive Breast Cancer (BC) Suitable for Neoadjuvant Therapy","enrollment":2000},{"nctId":"NCT02495896","phase":"PHASE1","title":"Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2015-09-03","conditions":"Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma","enrollment":61},{"nctId":"NCT06463665","phase":"PHASE2","title":"Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2024-09-26","conditions":"Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer","enrollment":142},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT06079983","phase":"PHASE3","title":"JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects","status":"RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2023-12-01","conditions":"Breast Cancer","enrollment":400},{"nctId":"NCT02514681","phase":"PHASE3","title":"A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer","status":"COMPLETED","sponsor":"Japan Breast Cancer Research Group","startDate":"2015-08-01","conditions":"HER2-positive Locally Advanced or Metastatic Breast Cancer","enrollment":226},{"nctId":"NCT07139041","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Chang Chen","startDate":"2025-10","conditions":"NSCLC (Non-small-cell Lung Cancer)","enrollment":69},{"nctId":"NCT07134413","phase":"PHASE2","title":"QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2025-08","conditions":"NSCLC","enrollment":77},{"nctId":"NCT05007106","phase":"PHASE2","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-16","conditions":"Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck","enrollment":613},{"nctId":"NCT07093931","phase":"PHASE4","title":"Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-08-01","conditions":"Breast Cancer","enrollment":468},{"nctId":"NCT04306900","phase":"PHASE1","title":"TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers","status":"COMPLETED","sponsor":"Trishula Therapeutics, Inc.","startDate":"2020-03-30","conditions":"Solid Tumor, Adult","enrollment":185},{"nctId":"NCT04879368","phase":"PHASE3","title":"RegoNivo vs Standard of Care Chemotherapy in AGOC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-06-01","conditions":"Gastro-Oesophageal Cancer","enrollment":450},{"nctId":"NCT06441890","phase":"PHASE2","title":"BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2024-12-05","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":28},{"nctId":"NCT06439693","phase":"PHASE2","title":"The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-08-08","conditions":"Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic","enrollment":72},{"nctId":"NCT06769425","phase":"PHASE1","title":"HS-10502 Combination Treatment in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2025-05-07","conditions":"Recurrent Ovarian Cancer, HER2-negative, Advanced Breast Cancer","enrollment":157},{"nctId":"NCT06927180","phase":"PHASE2","title":"SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-04-16","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","enrollment":180},{"nctId":"NCT06311981","phase":"PHASE2","title":"Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients","status":"RECRUITING","sponsor":"Jian Chen","startDate":"2024-08-08","conditions":"Non-small Cell Lung Cancer, Older People, Carbon Ion Radiotherapy","enrollment":29},{"nctId":"NCT05919537","phase":"PHASE1","title":"Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hummingbird Bioscience","startDate":"2023-09-06","conditions":"Non-Small Cell Lung Cancer, Pancreatic Cancer, Locally Advanced Solid Tumor","enrollment":68},{"nctId":"NCT05267470","phase":"PHASE1","title":"A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)","status":"TERMINATED","sponsor":"Amgen","startDate":"2022-03-29","conditions":"Squamous-Cell Non-Small-Cell Lung Cancer","enrollment":74},{"nctId":"NCT05918328","phase":"PHASE2","title":"Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2023-05-03","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":610},{"nctId":"NCT05431270","phase":"PHASE1, PHASE2","title":"Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)","status":"RECRUITING","sponsor":"Phanes Therapeutics","startDate":"2022-08-11","conditions":"Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma","enrollment":40},{"nctId":"NCT06714266","phase":"PHASE2","title":"Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2024-12-15","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":30},{"nctId":"NCT06711055","phase":"","title":"Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer","status":"RECRUITING","sponsor":"Shu Wang","startDate":"2015-01-01","conditions":"HER2-positive Breast Cancer","enrollment":285},{"nctId":"NCT06692725","phase":"","title":"De-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2019-01-01","conditions":"Triple Negative Breast Cancer","enrollment":380},{"nctId":"NCT06523673","phase":"PHASE3","title":"Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-09","conditions":"Metastatic Non-Small Cell Lung Cancer, NSCLC Stage IV, OligoProgressive Metastatic Disease","enrollment":104},{"nctId":"NCT06542549","phase":"PHASE3","title":"Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2024-10-01","conditions":"Advanced Ovarian Cancer, AK104(PD-1/CTLA-4 Bispecial Antibody), Chemotherapy","enrollment":100},{"nctId":"NCT03435250","phase":"PHASE1","title":"Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss","status":"TERMINATED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2018-03-04","conditions":"Advanced Solid Tumors, Lymphoma","enrollment":123},{"nctId":"NCT03393741","phase":"","title":"Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2018-01-29","conditions":"Breast Cancer, Breast Neoplasms","enrollment":5},{"nctId":"NCT06467500","phase":"PHASE2","title":"A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy","status":"RECRUITING","sponsor":"Xin-Hua Xu","startDate":"2024-03-01","conditions":"Non-small Cell Lung Cancer","enrollment":48},{"nctId":"NCT06424899","phase":"PHASE2","title":"A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC","status":"RECRUITING","sponsor":"Zeng Jian","startDate":"2024-05-19","conditions":"Non Small Cell Lung Cancer","enrollment":92},{"nctId":"NCT06190782","phase":"PHASE3","title":"Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-09-27","conditions":"Esophageal Squamous Cell Carcinoma, Oligometastatic Disease, Radiotherapy","enrollment":354},{"nctId":"NCT06136988","phase":"PHASE1, PHASE2","title":"A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2023-12","conditions":"Locally Advanced Unresectable Esophageal Squamous Carcinoma","enrollment":129},{"nctId":"NCT04172259","phase":"PHASE2","title":"ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-01-10","conditions":"Breast Cancer, Neoadjuvant Chemotherapy","enrollment":156},{"nctId":"NCT03840915","phase":"PHASE1, PHASE2","title":"M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2019-04-02","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":70},{"nctId":"NCT05953909","phase":"","title":"A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01).","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2023-02-01","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT02915744","phase":"PHASE3","title":"A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine","status":"COMPLETED","sponsor":"Nektar Therapeutics","startDate":"2016-11","conditions":"Metastasis, Breast Cancer","enrollment":178},{"nctId":"NCT02067416","phase":"PHASE2","title":"PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer","status":"WITHDRAWN","sponsor":"Jenny C. Chang, MD","startDate":"2012-07","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT01446016","phase":"PHASE2","title":"Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)","status":"COMPLETED","sponsor":"The Methodist Hospital Research Institute","startDate":"2011-09","conditions":"Breast Neoplasms, Breast Cancer","enrollment":38},{"nctId":"NCT02229149","phase":"PHASE2","title":"Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer","status":"TERMINATED","sponsor":"US Oncology Research","startDate":"2014-12","conditions":"Breast Neoplasms, Malignant Tumor of the Breast","enrollment":33},{"nctId":"NCT01779050","phase":"PHASE2","title":"Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2013-12-19","conditions":"Breast Neoplasms","enrollment":7},{"nctId":"NCT05322499","phase":"PHASE2","title":"Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2022-04-15","conditions":"Stage IV Esophagus Squamous Cell Carcinoma","enrollment":80},{"nctId":"NCT05287308","phase":"NA","title":"Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study","status":"NOT_YET_RECRUITING","sponsor":"Chinese Academy of Medical Sciences","startDate":"2022-03","conditions":"Breast Cancer","enrollment":500},{"nctId":"NCT04760431","phase":"PHASE2","title":"TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-10-01","conditions":"HER2-positive Breast Cancer, Brain Metastases","enrollment":120},{"nctId":"NCT02574078","phase":"PHASE1, PHASE2","title":"A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-11-23","conditions":"Non-Small Cell Lung Cancer","enrollment":341},{"nctId":"NCT04563975","phase":"PHASE2","title":"Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Tao Zhang","startDate":"2020-07-02","conditions":"Gastric Cancer Stage IV","enrollment":54},{"nctId":"NCT04702009","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2021-01-20","conditions":"Advanced Lung Carcinoma, Non-small Cell Lung Cancer","enrollment":80},{"nctId":"NCT01572038","phase":"PHASE3","title":"A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-06-01","conditions":"Breast Neoplasms","enrollment":1436},{"nctId":"NCT04499118","phase":"PHASE2","title":"AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer","status":"UNKNOWN","sponsor":"Sichuan Provincial People's Hospital","startDate":"2020-08","conditions":"HER2-negative Breast Cancer","enrollment":100},{"nctId":"NCT00274456","phase":"PHASE2","title":"Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer","status":"COMPLETED","sponsor":"Celgene","startDate":"2005-11-01","conditions":"Metastatic Breast Cancer","enrollment":302},{"nctId":"NCT01376310","phase":"PHASE2","title":"GSK1120212 Rollover Study","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-11-02","conditions":"Cancer","enrollment":159},{"nctId":"NCT02019277","phase":"PHASE3","title":"A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-12-05","conditions":"Breast Cancer","enrollment":50},{"nctId":"NCT01192165","phase":"PHASE1","title":"Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09-14","conditions":"Cancer","enrollment":169},{"nctId":"NCT01156753","phase":"PHASE2","title":"A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer","status":"COMPLETED","sponsor":"Celldex Therapeutics","startDate":"2010-07","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT00637897","phase":"PHASE1","title":"Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2008-03","conditions":"Breast Cancer","enrollment":24},{"nctId":"NCT02940990","phase":"PHASE2","title":"SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver Mutations","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2016-11","conditions":"NSCLC, SBRT, GM-CSF","enrollment":50},{"nctId":"NCT00659269","phase":"PHASE3","title":"A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients","status":"COMPLETED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2006-07","conditions":"Cancer","enrollment":319},{"nctId":"NCT01850147","phase":"PHASE2","title":"Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2013-03","conditions":"Cancer, Lung Cancer","enrollment":50},{"nctId":"NCT00479856","phase":"PHASE2","title":"Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2007-11","conditions":"Relapsed Breast Cancer, Neoplasms, Breast","enrollment":9}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22746,"recentPublications":[],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Docetaxel or albumin paclitaxel","genericName":"Docetaxel or albumin paclitaxel","companyName":"Shandong Cancer Hospital and Institute","companyId":"shandong-cancer-hospital-and-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Docetaxel and albumin-bound paclitaxel are taxane chemotherapy agents that stabilize microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis. Used for Metastatic breast cancer, Non-small cell lung cancer, Ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}